JPMorgan Chase & Co. Sells 27,324 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

JPMorgan Chase & Co. decreased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 21.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 101,059 shares of the medical instruments supplier's stock after selling 27,324 shares during the quarter. JPMorgan Chase & Co. owned about 0.45% of LeMaitre Vascular worth $9,387,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in LMAT. Driehaus Capital Management LLC increased its stake in LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier's stock valued at $21,740,000 after buying an additional 90,573 shares during the period. DF Dent & Co. Inc. boosted its holdings in shares of LeMaitre Vascular by 26.2% in the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier's stock valued at $24,037,000 after acquiring an additional 53,797 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier's stock valued at $183,769,000 after acquiring an additional 36,850 shares during the period. Rice Hall James & Associates LLC raised its holdings in LeMaitre Vascular by 15.7% during the third quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier's stock worth $24,273,000 after purchasing an additional 35,383 shares in the last quarter. Finally, F M Investments LLC lifted its position in LeMaitre Vascular by 36.6% in the third quarter. F M Investments LLC now owns 123,545 shares of the medical instruments supplier's stock worth $11,476,000 after purchasing an additional 33,087 shares during the period. Institutional investors own 84.64% of the company's stock.

Insider Activity

In related news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company's stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Trading Up 1.8 %

Shares of LMAT traded up $1.68 during midday trading on Tuesday, hitting $95.85. The stock had a trading volume of 93,169 shares, compared to its average volume of 163,409. The business has a 50-day simple moving average of $98.72 and a two-hundred day simple moving average of $91.58. The firm has a market cap of $2.16 billion, a P/E ratio of 52.38, a price-to-earnings-growth ratio of 2.47 and a beta of 0.96. LeMaitre Vascular, Inc. has a fifty-two week low of $55.04 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analysts' expectations of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company's quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.33 EPS. On average, analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were paid a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.67%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 34.97%.

Analysts Set New Price Targets

A number of research firms have recently commented on LMAT. StockNews.com downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Barrington Research lifted their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a report on Friday, November 1st. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 price target for the company. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, LeMaitre Vascular presently has an average rating of "Moderate Buy" and an average price target of $94.57.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.